<?xml version='1.0' encoding='utf-8'?>
<document id="32291610"><sentence text="A Translational Physiologically Based Pharmacokinetics/Pharmacodynamics Framework of Target-Mediated Disposition, Target Inhibition and Drug-Drug Interactions of Bortezomib."><entity charOffset="162-172" id="DDI-PubMed.32291610.s1.e0" text="Bortezomib" /></sentence><sentence text="Bortezomib is a potent 20S proteasome inhibitor approved for the treatment of multiple myeloma and mantle cell lymphoma"><entity charOffset="0-10" id="DDI-PubMed.32291610.s2.e0" text="Bortezomib" /></sentence><sentence text=" Despite the extensive clinical use of bortezomib, the mechanism of the complex time-dependent pharmacokinetics of bortezomib has not been fully investigated in context of its pharmacodynamics (PD) and drug-drug interaction (DDI) profiles"><entity charOffset="39-49" id="DDI-PubMed.32291610.s3.e0" text="bortezomib" /><entity charOffset="115-125" id="DDI-PubMed.32291610.s3.e1" text="bortezomib" /><pair ddi="false" e1="DDI-PubMed.32291610.s3.e0" e2="DDI-PubMed.32291610.s3.e0" /><pair ddi="false" e1="DDI-PubMed.32291610.s3.e0" e2="DDI-PubMed.32291610.s3.e1" /></sentence><sentence text=" Here, we aimed to develop a mechanistic physiologically based (PB) PK/PD model to project PK, blood target inhibition and DDI of bortezomib in patients"><entity charOffset="130-140" id="DDI-PubMed.32291610.s4.e0" text="bortezomib" /></sentence><sentence text=" A minimal PBPK/PD model consisting of six compartments was constructed using a bottom-up approach with pre-clinical data and human physiological parameters" /><sentence text=" Specifically, the target-mediated drug disposition (TMDD) of bortezomib in red blood cells (RBC), which determines target inhibition in blood, was characterized by incorporating the proteasome binding affinity of bortezomib and the proteasome concentration in RBC"><entity charOffset="62-72" id="DDI-PubMed.32291610.s6.e0" text="bortezomib" /><entity charOffset="214-224" id="DDI-PubMed.32291610.s6.e1" text="bortezomib" /><pair ddi="false" e1="DDI-PubMed.32291610.s6.e0" e2="DDI-PubMed.32291610.s6.e0" /><pair ddi="false" e1="DDI-PubMed.32291610.s6.e0" e2="DDI-PubMed.32291610.s6.e1" /></sentence><sentence text=" The hepatic clearance and fraction metabolized by different CYP isoforms were estimated from in vitro metabolism and phenotyping experiments" /><sentence text=" The established model adequately characterized the multi-exponential and time-dependent plasma pharmacokinetics, target binding and blood proteasome inhibition of bortezomib"><entity charOffset="164-174" id="DDI-PubMed.32291610.s8.e0" text="bortezomib" /></sentence><sentence text=" Further, the model was able to accurately predict the impact of a strong CYP3A inducer (rifampicin) and inhibitor (ketoconazole) on bortezomib exposure"><entity charOffset="89-99" id="DDI-PubMed.32291610.s9.e0" text="rifampicin" /><entity charOffset="116-128" id="DDI-PubMed.32291610.s9.e1" text="ketoconazole" /><entity charOffset="133-143" id="DDI-PubMed.32291610.s9.e2" text="bortezomib" /><pair ddi="false" e1="DDI-PubMed.32291610.s9.e0" e2="DDI-PubMed.32291610.s9.e0" /><pair ddi="false" e1="DDI-PubMed.32291610.s9.e0" e2="DDI-PubMed.32291610.s9.e1" /><pair ddi="false" e1="DDI-PubMed.32291610.s9.e0" e2="DDI-PubMed.32291610.s9.e2" /><pair ddi="false" e1="DDI-PubMed.32291610.s9.e1" e2="DDI-PubMed.32291610.s9.e1" /><pair ddi="false" e1="DDI-PubMed.32291610.s9.e1" e2="DDI-PubMed.32291610.s9.e2" /></sentence><sentence text=" In conclusion, the mechanistic PBPK/PD model successfully described the complex pharmacokinetics, target inhibition and DDIs of bortezomib in patients"><entity charOffset="129-139" id="DDI-PubMed.32291610.s10.e0" text="bortezomib" /></sentence><sentence text=" This study illustrates the importance of incorporating target biology, drug-target interactions and in vitro clearance parameters into mechanistic PBPK/PD models and the utility of such models for pharmacokinetic, pharmacodynamic and DDI predictions" /><sentence text="" /></document>